HSBC Value Fund

HSBC Mutual FundAMFI 151113NAV ₹130.42 as of 11 Aug '26

How it behaved in each kind of market
as of 12 Aug '26

In rising markets this fund ran +44.3% a year, +6.0% ahead of its category.

Markets rising for 25 months. This fund returned +44.3% a year, 6.0% ahead of similar funds.
Markets flat for 12 months. This fund returned +3.8% a year, 4.4% ahead of similar funds.
Markets falling for 7 months. This fund returned — a year, with no category comparison available.
What counts as a rising, flat or falling market?

Every month of the last 10 years is labelled from the NIFTY 500's month-end close, before any fund is looked at. Falling means the index sat 8% or more below its own running peak. Rising means it was above its 10-month average and within 5% of that peak. Flat is everything in between.

Return a yearis what this fund's own NAV did over just those months, compounded — not averaged. vs similar funds is the same figure for the median fund in its SEBI category over the very same months, so both sides face the identical market.

The falling spells measured here: Sep '18 (-12%), Jan '19 (-10%), Jul '19 (-9%), Mar '20 (-32%), Feb '23 (-9%), Jan '25 (-18%).

Which state a month was in is only knowable afterwards, so this describes what already happened and does not forecast what comes next.

expense 0.89% direct · 44 months of NAV read · some states thinBuilt from AMFI NAV history

Fund facts

Category
Value
Fund size
₹14,682 Cr
Expense ratio
0.89% (Direct)
Riskometer
Very High

What the fund aims to do

To generate long-term capital appreciation from diversified portfolio of predominantly equity and equity related securities, in the Indian markets with higher focus on undervalued securities. The Scheme could also additionally invest in Foreign Securities in international markets.

Analysis of public AMFI data for research. Market states are labelled mechanically from NIFTY 500 month-end closes and are only knowable in hindsight. Past behaviour is not a forecast. We are not a registered investment adviser and nothing here is a recommendation to buy or sell.